We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$209B
$155M 5.79%
608,218
-3,744
-0.6% -$928K
REGN icon
2
Regeneron Pharmaceuticals
REGN
$77.4B
$116M 4.35%
207,388
+19,453
+10% +$11.8M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$122B
$109M 4.09%
401,360
-75,970
-16% -$21M
GILD icon
4
Gilead Sciences
GILD
$163B
$104M 3.89%
1,643,683
+62,657
+4% +$4.35M
MRK icon
5
Merck
MRK
$321B
$87.7M 3.28%
1,107,428
+89,300
+9% +$6.99M
ILMN icon
6
Illumina
ILMN
$31B
$86.9M 3.26%
288,924
+68,263
+31% +$23.5M
JNJ icon
7
Johnson & Johnson
JNJ
$617B
$81.4M 3.05%
546,805
-283,226
-34% -$41.9M
ABBV icon
8
AbbVie
ABBV
$455B
$76.6M 2.87%
874,720
+340,995
+64% +$32.1M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$66M 2.47%
337,204
+96,645
+40% +$16.2M
PFE icon
10
Pfizer
PFE
$142B
$62.2M 2.33%
1,787,339
+41,337
+2% +$1.45M
BIIB icon
11
Biogen
BIIB
$30.7B
$60.6M 2.27%
213,753
-19,846
-8% -$5.54M
UNH icon
12
UnitedHealth
UNH
$383B
$57.9M 2.17%
185,735
-94,416
-34% -$29M
BMY icon
13
Bristol-Myers Squibb
BMY
$132B
$57M 2.14%
945,140
-32,365
-3% -$1.95M
MDT icon
14
Medtronic
MDT
$110B
$55.6M 2.08%
534,914
+59,425
+12% +$5.97M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$46.9M 1.76%
603,684
+193,531
+47% +$13.3M
ABT icon
16
Abbott
ABT
$183B
$40.2M 1.51%
369,573
-116,677
-24% -$11.8M
HUM icon
17
Humana
HUM
$44B
$35.6M 1.33%
86,007
+37,501
+77% +$15.1M
SYK icon
18
Stryker
SYK
$133B
$32.9M 1.23%
157,830
-6,400
-4% -$1.24M
MRNA icon
19
Moderna
MRNA
$23B
$32.6M 1.22%
460,359
-32,147
-7% -$2.24M
BDX icon
20
Becton Dickinson
BDX
$45.6B
$30.6M 1.15%
135,016
+55,318
+69% +$13.6M
ALXN
21
DELISTED
Alexion Pharmaceuticals
ALXN
$30.5M 1.14%
266,791
-117,918
-31% -$12.7M
SRPT icon
22
Sarepta Therapeutics
SRPT
$1.64B
$29M 1.09%
206,487
+66,358
+47% +$10.1M
BSX icon
23
Boston Scientific
BSX
$68.4B
$28.3M 1.06%
741,296
+96,361
+15% +$3.71M
EXEL icon
24
Exelixis
EXEL
$14.1B
$26.8M 1%
1,095,117
+161,168
+17% +$3.76M
CNC icon
25
Centene
CNC
$30.1B
$26.7M 1%
458,313
+170,119
+59% +$10.6M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.